

Q5 Balázs Bognár,<sup>a</sup> Boglárka Varga,<sup>a</sup> Tamás Kálai,<sup>a,b</sup> Viola Csokona,<sup>a</sup> Gergely Gulyás Fekete,<sup>c</sup> Cecília Sár,<sup>a</sup> and Kálmán Hideg<sup>a\*</sup>

<sup>a</sup>Institute of Organic and Medicinal Chemistry, University of Pécs, Szigeti st. 12, Pécs H-7624, Hungary

<sup>b</sup>Szentágotthai Research Centre, Ifjúság st. 20, Pécs H-7624, Hungary


<sup>c</sup>Institute of Pharmacognosy University of Pécs, Rokus st. 2, Pécs H-7624, Hungary

\*E-mail: kalman.hideg@aok.pte.hu

Received July 18, 2016

DOI 10.1002/jhet.2850

Published online 00 Month 2017 in Wiley Online Library (wileyonlinelibrary.com).



Reactions of  $\beta$ -bromo- $\beta,\gamma$ -unsaturated pyrroline nitroxide aldehyde (**1**) or nitrile (**4**) or their diamagnetic forms (**5**, **6**) with 2-aminothiophenol or 2-mercaptobenzimidazole were evaluated. The reaction could be reproduced more easily with the application of *O*-acetyl derivatives of nitroxides to generate 2-substituted-benzothiazole, pyrrolo[3,4-*b*]benzo[1,5]thiazepine scaffolds with 2-aminothiophenol and benzimidazo[2,1-*b*]pyrrolo[3,4-*e*]-[1,3]thiazine scaffold with 2-mercaptobenzimidazole.

*J. Heterocyclic Chem.*, **00**, 00 (2017).


## INTRODUCTION

Extensive studies of stable nitroxide free radicals have established the value of these unique compounds in applications such as spin labels [1], co-oxidants [2], building blocks for magnetic materials [3], synthesis of paramagnetic biomolecules [4], and mediators of polymerization [5]. These diverse applications were possible after M.B. Neiman and E.G. Rozantsev, and their group expanded the synthesis of nitroxide free radicals into a broad range of compounds [6], recognizing the limits of functionalization of TEMPO or **F1** 4-OXOTEMPO (Fig. 1).

To access further transformable stable nitroxide free radical building blocks, our laboratory started the synthesis of carbocycle and heterocycle condensed

nitroxide free radicals, which offer many possible synthetic amendments. In these previous works, we synthesized thiophene [7], selenophene [8], pyridine [9], pyrrole [9,10], coumarin [11], phenanthrene [11], and polyheterocycles [12] condensed stable nitroxide free radicals. We reported the synthesis of 1,4-thiazepine derivative **2** [7] and 2-thienylbenzimidazole derivative **3** [13] by treatment of 4-bromo-3-formyl-2,2,5,5-tetramethyl-2,5-dihydro-1*H*-pyrrol-1-ylxoyl radical **1** with cysteamine and 2-mercaptomethylbenzimidazole, respectively (Fig. 2). However, reactions of **1** with 2-aminothiophenol resulted in the formation of a mixture of compounds.

In this article, we report the results of some reactions of  $\beta$ -bromo- $\beta,\gamma$ -unsaturated pyrroline nitroxide aldehyde or nitrile with aromatic *N*-binucleophiles and *S*-binucleophiles



**Figure 1.** Structure of stable nitroxide free radicals TEMPO and 4-OXOTEMPO.

to elucidate their unusual performance in reactions and to find a pathway to synthesize the series of paramagnetically modified 1,5-benzothiazepine scaffolds, whose biological importance is well reported in the literature [14–18].


## RESULTS AND DISCUSSION

Based on previous reports [19], our hypothesis was that nitroxides oxidize the aromatic thiols to the corresponding disulfides causing a nonreproducible reaction as in the case of compound **1** and 2-aminothiophenol.


We proposed that a diamagnetic derivative of aldehyde **1** and nitrile **4** should be used in these reactions in such forms, which prevent the oxidation of aromatic thiols, because the formed aromatic disulfides cannot react further as *S*-nucleophiles. Therefore, compounds **1** and **4** were first converted to the *O*-acetyl derivatives **5** and **6** by a previously reported methodology [20], through the reduction to the corresponding hydroxylamine with ascorbic acid, followed by treatment with acetyl chloride **S1** in the presence of Et<sub>3</sub>N in chloroform (Scheme 1).

Heating the 1:1 mixture of 2-aminothiophenol and compound **5** in the absence of a base in dimethyl sulfoxide in a (4 + 1) cyclocondensation generated 2-substituted benzothiazole. For more convenient isolation of compound **7**, the crude product was deacetylated with NaOMe in MeOH and oxidized with 0.1 equiv activated MnO<sub>2</sub> with bubbling through O<sub>2</sub> gas **S2** (Scheme 2). The (4 + 1) cyclocondensation was proven by elemental analysis and mass spectral measurements of the product, indicating the presence of bromine in

**Scheme 1.** Synthesis of diamagnetic *O*-acetyl derivatives of **1** and **6**.




**Scheme 2.** Reaction of compound **5** with 2-aminothiophenol in dimethyl sulfoxide (DMSO) in the absence of base.





molecular ion at 351/353/355 (M<sup>+</sup>). The formation of benzothiazole is an acid-catalyzed process [21,22] initiated by the protonation of the imine with the participation of the SH acidic center, hence generating a nucleophilic thiolate and imine carbon more electrophilic than β-carbon.

Reaction of compound **5** and 2-aminothiophenol in acetonitrile in the presence of 1.1 equiv DBU gave 1,1,3,3-tetramethyl-2,3-dihydro-1*H*-pyrrolo[3,4-*b*]benzo[1,5]thiazepin-2-acetate **8** in an (4 + 3) cyclocondensation reaction. In this case, we propose that the bromine substitution with thiolate—generated in basic conditions—in the first stage be followed by the Schiff base formation. We assume the nucleophilic substitution of bromine atom to be the “push–pull” process with addition of thiolate to β-carbon, followed by halogen cleavage with C3–C4 double bond restoration. Deacetylation of compound **8**, as described earlier, offered compound **9**. Reduction of compound **9** with 1.2 equiv NaBH<sub>4</sub> in EtOH gave secondary amine **10**. This reduction is proven by appearance of CH<sub>2</sub> signal at 3.79 ppm in <sup>1</sup>H NMR spectrum, and this type of



**Figure 2.** Reaction of aldehyde **1** with various *N*-binucleophiles and *S*-binucleophiles.


**Scheme 3.** Synthesis of paramagnetic benzo[1,5]thiazepine derivatives from aldehyde **5**.**Scheme 4.** Synthesis of paramagnetic benzo[1,5]thiazepine derivative **14** from nitrile **6**.

transformation is well documented in the literature [23] as well. Methylation of compound **10** with  $\text{CH}_3\text{I}$  in acetonitrile in the presence of  $\text{K}_2\text{CO}_3$  generated compound 1,1,3,3,9-pentamethyl-9,10-dihydro-1*H*-pyrrolo[3,4-*b*]benzo[1,5]thiazepin-2-yloxy radical **11**. Oxidation of compound **11** in aqueous (aq) MeOH with  $\text{H}_2\text{O}_2$  in the presence of  $\text{Na}_2\text{WO}_4$  furnished sulfone **12** (Scheme 3).

Reaction of compound **6** with 2-aminothiophenol in acetonitrile and 1.1 equiv DBU furnished adduct **13**. The presence of the nitrile band in infrared (IR) at  $2210\text{ cm}^{-1}$  indicated that no ring closure occurred, because the nitrile group of compound **6** is a weaker electrophile than the formyl group in compounds **1** and **5**, the latter giving ring closure smoothly with aromatic amines. The thiazepine ring formation can be initiated by refluxing compound **13** in EtOH, saturated with HCl gas. Along with the ring closure, deacetylation also occurred, and hence, after basic work-up followed by oxidation with  $\text{MnO}_2/\text{O}_2$ , we obtained 10-amino-1,1,3,3-tetramethyl-2,3-dihydro-1*H*-pyrrolo[3,4-*b*]benzo[1,5]thiazepin-2-yloxy

**S4** radical **14** (Scheme 4).

Reaction of compound **1** with 2-mercaptobenzimidazole in acetonitrile in the presence of 2.1 equiv DBU with heating provided 11-hydroxy-1,1,3,3-tetramethyl-1,2,3,11-tetrahydro-benzimidazo[2,1-*b*]pyrrolo[3,4-*e*][1,3]

**Scheme 5.** Reaction of aldehyde **1** with 2-mercaptobenzimidazole.

thiazin-2-yloxy radical **15** in a (3 + 3) cyclocondensation reaction, in an analogous reaction published earlier by Hungarian researchers [24] (Scheme 5).

## CONCLUSIONS

Reactions of  $\beta$ -bromo- $\beta,\gamma$ -unsaturated pyrroline nitroxide aldehyde (**1**) or nitrile (**4**) or their *O*-acetyl derivatives (**5**, **6**) with various *N*-binucleophiles and *S*-binucleophiles depending on reaction partners or absence/presence of a base gave structurally diversified paramagnetic polycyclic compounds. We suggested camouflaging of the nitroxide function in the presence of aromatic thiols in most cases to avoid unwanted side reactions. Although reactions of nitroxides have been studied for several decades, there are still many challenges (selectivity problems) that remain to be solved. We believe that the reactions studied in this work are extendable to the reactions of any  $\beta$ -halogen- $\alpha,\beta$ -unsaturated aldehydes or nitriles, giving a straightforward synthetic access to a number of interesting fused *S*-containing and *N*-containing polyheterocycles.

**Experimental.** Melting points were determined using Boetius micro melting point apparatus and are uncorrected. Elemental analyses (C, H, N, S) were performed on Fisons EA 1110 CHNS elemental analyser; bromine determination was carried out titrimetrically by Schöniger's method. Mass spectra were recorded on a Thermoquest Automass Multi.  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra were recorded with Bruker Avance 3 Ascend 500 spectrometer. Chemical shifts are referenced to  $\text{Me}_4\text{Si}$ . The paramagnetic compound was reduced with 5 equiv

hydrazobenzene or pentafluorophenyl hydrazine/radical. Measurements were run at 298 K probe temperature in CDCl<sub>3</sub> or CD<sub>3</sub>OD solution. Electron spin resonance spectra were taken on Miniscope MS 200 in 10<sup>-4</sup> M CHCl<sub>3</sub> solution, and all monoradicals gave triplet line a<sub>N</sub> = 14.4 G. The IR spectra were taken with Bruker Alpha FTIR instrument with ATR support (ZnSe plate). Flash column chromatography was performed on Merck Kieselgel 60 (0.040–0.063 mm). Qualitative thin-layer chromatography (TLC) was carried out on commercially available plates (20 × 20 × 0.02 cm) coated with Merck Kieselgel GF254. Compounds **1** [25] and **4** [7] were prepared according to published procedures, and other reagents were purchased from Aldrich or Alfa Aesar.

**Synthesis of diamagnetic O-acetyl derivatives, general procedure (5, 6).** Into a two-necked flask equipped with magnetic stirrer, N<sub>2</sub> inlet, and condenser, we placed the MgSO<sub>4</sub> drying agent (10 g) and Et<sub>3</sub>N (1.11 g, 11.0 mmol). In another round bottomed flask with two necks, we placed compound **1** or **4** dissolved in dioxane/water (3:1) (32 mL). The mixture was stirred at 35–40°C under N<sub>2</sub>, and ascorbic acid (8.80 g, 50.0 mmol) was added in four to five portions. After the solution became colorless or pale yellow, it was extracted in CHCl<sub>3</sub> (2 × 20 mL), and the colorless bottom organic phases were sunk down into the MgSO<sub>4</sub>, Et<sub>3</sub>N-containing flask directly. Then, the mixture was cooled to 0°C, and AcCl (863 mg, 11.0 mmol) was added dropwise. After removing the cooling bath, the mixture was allowed to stir at ambient temperature for 1 h under N<sub>2</sub>. After quenching with MeOH (1 mL), the mixture was filtered on a glass frit, the filtrate was evaporated, and the residue was partitioned between brine (10 mL) and EtOAc (25 mL). The organic phase was separated, dried (MgSO<sub>4</sub>), filtered, and evaporated to offer a colorless thick oil, which was further purified by flash column chromatography (hexane/Et<sub>2</sub>O).

**3-Bromo-4-formyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-1-yl acetate (5).** white crystal, 1.39 g (48%), mp 71–72°C; R<sub>f</sub>: 0.43 (hexane/Et<sub>2</sub>O, 2:1); IR: 2937, 2845, 1768, 1676, 1603 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 1.35 (s, 3H), 1.38 (s, 3H), 1.41 (s, 6H), 2.15 (s, 3H), 9.82 (s, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 19.0, 21.8, 21.9, 27.2, 27.4, 70.8, 72.6, 139.1, 145.6, 170.5, 188.1; MS (70 eV): *m/z* 291/289 (M<sup>+</sup>, 14/14), 276/274 (76/76), 249/247 (61/61), 234/232 (98), 43 (100). *Anal.* Calcd. for C<sub>11</sub>H<sub>16</sub>BrNO<sub>3</sub>: C, 45.53; H, 5.56; N, 4.83; Br, 27.54. Found: C, 45.38; H, 5.52; N, 4.76; Br, 27.40.

**3-Bromo-4-cyano-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-1-yl acetate (6).** white crystalline solid, 1.40 g (57%), mp 60–61°C; R<sub>f</sub>: 0.38 (hexane/Et<sub>2</sub>O, 2:1); IR: 2982, 2932, 2866, 2225, 1770, 1680, 1623 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 1.34 (s, 3H), 1.37 (s, 3H),

1.40 (s, 3H), 1.46 (s, 3H), 2.15 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 18.9, 22.6 (2C), 27.5, 27.9, 71.7, 73.9, 113.1, 119.3, 141.6, 169.8; MS (70 eV): *m/z* 288/286 (M<sup>+</sup>, 3/3), 273/271 (7/7), 246/244 (20/20), 229/221 (100), 150 (45), 43 (73). *Anal.* Calcd. for C<sub>11</sub>H<sub>15</sub>BrN<sub>2</sub>O<sub>2</sub>: C, 46.01; H, 5.27; N, 9.76; Br, 27.83. Found: C, 46.06; H, 5.06; N, 9.94; Br, 27.60.

**3-(Benzthiazol-2-yl)-4-bromo-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-1-yloxy radical (7).** A solution of compound **5** (580 mg, 2.0 mmol) and 2-aminothiophenol (250 mg, 2.0 mmol) in dimethyl sulfoxide (5 mL) was heated at 90°C for 2 h. After cooling, the solvent was evaporated off, the residue was dissolved in MeOH (10 mL), and freshly made NaOMe solution was added (5 mL MeOH +5 mg Na metal). After standing at room temperature (RT) for 30 min, the solvent was evaporated off, and the residue was partitioned between saturated aq NH<sub>4</sub>Cl solution (10 mL) and CHCl<sub>3</sub> (10 mL). The organic phase was extracted with CHCl<sub>3</sub> (10 mL) again, and the combined organic phases were dried (MgSO<sub>4</sub>), activated MnO<sub>2</sub> (43 mg, 0.5 mmol) was added, and O<sub>2</sub> was bubbled through for 10 min. The mixture was filtered, evaporated, and purified by flash column chromatography (hexane/Et<sub>2</sub>O) to give compound **7** as a yellow solid, 183 mg (26%), mp 84–85°C; R<sub>f</sub>: 0.67 (hexane/Et<sub>2</sub>O, 2:1); IR: 3059, 2976, 2929, 2863, 1683, 1610, 1558 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD + C<sub>6</sub>F<sub>5</sub>N<sub>2</sub>H<sub>3</sub>): δ 1.36 (s, 6H), 1.55 (s, 6H), 7.66–8.17 (m, 4H); <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD + C<sub>6</sub>F<sub>5</sub>N<sub>2</sub>H<sub>3</sub>): δ 23.8 (2C), 24.0 (2C), 71.3, 71.9, 121.1, 122.8, 125.5, 126.1, 131.7, 134.3, 152.1, 160.24; MS (70 eV): *m/z* 355/353/351 (M<sup>+</sup>, 1>, 10/10), 310/308/306 (1>/13/13), 242 (100), 226 (20). *Anal.* Calcd. for C<sub>15</sub>H<sub>16</sub>BrN<sub>2</sub>OS: C, 51.14; H, 4.58; N, 7.95; S, 9.10; Br, 22.68. Found: C, 51.32; H, 4.72; N, 8.04; S, 8.95; Br, 22.50.

**1,1,3,3-Tetramethyl-2,3-dihydro-1H-pyrrolo-[3,4-b]benzo [1,5]thiazepin-2-acetate (8).** To a solution of compound **5** (1.45 g, 5.0 mmol) and 2-aminothiophenol (625 mg, 5.0 mmol) in acetonitrile (10 mL), DBU (836 mg, 5.5 mmol) was added and the mixture was allowed to stir at RT. for 2 h. The acetonitrile was evaporated off, the residue was dissolved in EtOAc (20 mL), the organic phase was washed with water (10 mL), and the organic phase was separated, dried (MgSO<sub>4</sub>), filtered, and evaporated. The residue was subjected to flash column chromatography to yield compound **8** as white crystals, 1.18 g (75%), mp 70–72°C; R<sub>f</sub>: 0.69 (CHCl<sub>3</sub>/Et<sub>2</sub>O, 2:1); IR: 2973, 2929, 1762, 1603 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 1.30 (s, 6H), 1.32 (s, 6H), 2.13 (s, 3H), 7.15–7.21 (m, 3H), 7.32–7.35 (m, 1H), 8.22 (s, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 19.0, 22.3, 23.0, 27.1, 27.6, 69.9, 71.9, 115.2, 118.1, 129.2, 131.5, 138.4, 139.4, 148.7, 150.3, 157.5, 170.7; MS (70 eV): *m/z* 316 (M<sup>+</sup>, 4), 301



(10), 259 (63), 227 (100), 211 (42), 43 (24). *Anal.* Calcd. for C<sub>17</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>S: C, 64.53; H, 6.37; N, 8.85; S, 10.13. Found: C, 64.32; H, 6.45; N, 9.01; S, 10.07.

**1,1,3,3-Tetramethyl-2,3-dihydro-1H-pyrrolo-[3,4-b]benzo[1,5]thiazepin-2-yloxy radical (9).** To a solution of compound **8** (948 mg, 3.0 mmol) in MeOH (10 mL), freshly made NaOMe (5 mL MeOH +7.5 mg Na) was added. After standing at RT for 30 min, the solvent was evaporated off, and the residue was dissolved in saturated aq NH<sub>4</sub>Cl solution (10 mL) and extracted with CHCl<sub>3</sub> (2 × 10 mL). The combined organic phase was dried (MgSO<sub>4</sub>), activated MnO<sub>2</sub> (65 mg, 0.75 mmol) was added to the mixture, and O<sub>2</sub> was bubbled through for 10 min. The mixture was filtered, evaporated, and purified by flash column chromatography (hexane/Et<sub>2</sub>O) to give the product as yellow crystals, 417 mg (51%), mp 104–106°C; R<sub>f</sub>: 0.45 (hexane/EtOAc, 2:1); IR: 2971, 2926, 2856, 1618, 1596, 1576 cm<sup>-1</sup>; MS (70 eV): *m/z* 273 (M<sup>+</sup>, 38), 259 (20), 243 (74), 136 (51), 108 (100). *Anal.* Calcd. for C<sub>15</sub>H<sub>17</sub>N<sub>2</sub>OS: C, 65.90; H, 6.27; N, 10.25; S, 11.73. Found: C, 65.96; H, 6.00; N, 10.06; S, 11.64.

**1,1,3,3-Tetramethyl-9,10-dihydro-1H-pyrrolo-[3,4-b]benzo[1,5]thiazepin-2(3H)-yloxy radical (10).** To a stirred solution of compound **9** (546 mg, 2.0 mmol) in EtOH (15 mL), NaBH<sub>4</sub> (76 mg, 2.0 mmol) was added at 0°C. After removing the cooling bath, the mixture was stirred for 2 h. The EtOH was evaporated off, and the residue was partitioned between saturated aq NH<sub>4</sub>Cl solution (10 mL) and CHCl<sub>3</sub> (15 mL). The phases were separated, the aq phase was re-extracted with CHCl<sub>3</sub> (15 mL), and the combined phases were dried (MgSO<sub>4</sub>), filtered, and evaporated. The residue was purified by flash column chromatography (hexane/EtOAc and CHCl<sub>3</sub>/Et<sub>2</sub>O) to offer compound **10** as a yellow solid, 374 mg (68%), mp 138–139°C; R<sub>f</sub>: 0.49 (CHCl<sub>3</sub>/Et<sub>2</sub>O, 2:1); IR: 3250, 2974, 2928, 2864, 1653, 1585 cm<sup>-1</sup>. For NMR study, the paramagnetic compound **10** was reduced to the diamagnetic secondary amine with Fe/AcOH as published earlier [26]. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 1.206 (s, 6H), 1.34 (s, 6H), 3.79 (s, 2H), 6.93 (d, 1H, *J* = 7.5 Hz), 6.98 (t, 1H, *J* = 7.5 Hz), 7.19 (t, 1H, *J* = 7.5 Hz), 7.38 (d, 1H, *J* = 7.5 Hz); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 29.1 (2C), 29.4 (2C), 46.4, 65.7, 66.9, 123.0, 123.3, 128.7, 129.3, 130.8, 132.7, 138.1, 150.4; MS (70 eV): *m/z* 275 (M<sup>+</sup>, 31), 245 (100), 230 (39), 136 (64). *Anal.* Calcd. for C<sub>15</sub>H<sub>19</sub>N<sub>2</sub>OS: C, 65.42; H, 6.95; N, 10.17; S, 11.64. Found: C, 65.49; H, 6.76; N, 10.06; S, 11.52.

**1,1,3,3,9-Pentamethyl-9,10-dihydro-1H-pyrrolo-[3,4-b]benzo[1,5]thiazepin-2(3H)-yloxy radical (11).** To a stirred mixture of compound **10** (275 mg, 1.0 mmol) and powdered K<sub>2</sub>CO<sub>3</sub> (138 mg, 1.0 mmol) in acetonitrile (7 mL), CH<sub>3</sub>I (426 mg, 3.0 mmol) was added and the

mixture was stirred and refluxed. After 5 h, further CH<sub>3</sub>I (142 mg, 1.0 mmol) was added, and after the consumption of the starting material (~10 h), the solution was diluted with CHCl<sub>3</sub> (10 mL), the reaction mixture was filtered through sintered glass funnel, and the solvents were evaporated off. The residue was dissolved in EtOAc (15 mL) and washed with water (10 mL), and the organic phase was separated, dried (MgSO<sub>4</sub>), filtered, and evaporated. The crude product was subjected to column chromatography (hexane/EtOAc, then CHCl<sub>3</sub>/Et<sub>2</sub>O) to give compound **11** as yellow crystals, 225 mg (78%), mp 122–124°C; R<sub>f</sub>: 0.76 (CHCl<sub>3</sub>/Et<sub>2</sub>O, 2:1); IR: 3055, 2977, 2930, 2816, 2788, 1653, 1579 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub> + (PhNH)<sub>2</sub>): δ 1.20 (s, 6H), 1.36 (s, 6H), 3.0 (s, 3H), 3.5 (s, 2H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub> + (PhNH)<sub>2</sub>): δ 24.0 (2C), 24.4 (2C), 44.54, 55.1, 69.8, 71.0, 120.2, 123.6, 129.2, 131.3, 134.9, 148.9, 152.7, 153.9; MS (70 eV): *m/z* 289 (M<sup>+</sup>, 16), 295 (30), 244 (10), 151 (100). *Anal.* Calcd. for C<sub>16</sub>H<sub>21</sub>N<sub>2</sub>OS: C, 66.40; H, 7.31; N, 9.68; S, 11.08. Found: C, 66.70; H, 7.19; N, 9.68; S 10.95.

**2-Oxyl-1,1,3,3,9-pentamethyl-9,10-dihydro-1H-pyrrolo-[3,4-b]benzo[1,5]thiazepin-4,4-dioxide radical (12).** To a stirred solution of compound **11** (289 mg, 1.0 mmol) and Na<sub>2</sub>WO<sub>4</sub>·2H<sub>2</sub>O (33 mg, 0.1 mmol) in MeOH (10 mL) and water (3 mL) aq 30%, H<sub>2</sub>O<sub>2</sub> (1 mL) was added at 0°C, and the mixture was allowed to stay at RT. After 24 h, further 30% H<sub>2</sub>O<sub>2</sub> (0.5 mL) was added, and the mixture was allowed to stay for further 24 h when TLC monitoring showed the consumption of the starting materials and sulfoxide intermediates. The mixture was diluted with brine, extracted with CHCl<sub>3</sub> (2 × 20 mL), and the organic phase was dried (MgSO<sub>4</sub>), filtered, and evaporated. The residue was purified by flash column chromatography to furnish compound **12** as a yellow solid, 176 mg (55%), mp 162–164°C; R<sub>f</sub>: 0.48 (CHCl<sub>3</sub>/Et<sub>2</sub>O, 2:1); IR: 2976, 2929, 1590, 1572, 1294, 1132 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub> + (PhNH)<sub>2</sub>): δ 1.26 (s, 6H), 1.63 (s, 6H), 3.04 (s, 3H), 3.77 (s, 2H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub> + (PhNH)<sub>2</sub>): δ 24.0 (2C), 24.8 (2C), 43.5, 55.1, 69.8, 70.8, 119.8, 123.2, 127.1, 134.7, 137.0, 139.9, 148.9, 149.9; MS (70 eV): *m/z* 321 (M<sup>+</sup>, 41), 291 (2), 227 (30), 212 (100). *Anal.* Calcd. for C<sub>16</sub>H<sub>21</sub>N<sub>2</sub>O<sub>3</sub>S: C, 59.79; H, 6.59; N, 8.72; S, 9.98. Found: C, 59.66; H, 6.51; N, 8.68; S, 9.87.

**3-((2-Aminophenyl)thio)-4-cyano-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-1-yl acetate (13).** To a stirred solution of compound **6** (1.43 g, 5.0 mmol) and DBU (836 mg, 5.5 mmol) in acetonitrile (10 mL), 2-aminothiophenol (625 mg, 5.0 mmol) was added and the mixture was stirred at ambient temperature till the consumption of starting materials (~2 h, monitored by TLC). The acetonitrile was evaporated off, the residue was dissolved in EtOAc (20 mL) and washed with water (10 mL), and

the organic phase was separated, dried (MgSO<sub>4</sub>), filtered, and evaporated. The residue was purified by flash column chromatography (hexane/EtOAc) to offer compound **13** as beige crystals, 1.18 g (75%), mp 122–124°C; R<sub>f</sub>: 0.33 (hexane/EtOAc, 2:1); IR: 3452, 3356, 2982, 2931, 2210, 1761, 1629, 1589 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub> + (PhNH)<sub>2</sub>): δ 1.34 (s, 6H), 1.45 (s, 6H), 2.16 (s, 3H), 4.29 (s, 2H), 6.79 (m, 2H), 7.32 (m, 1H), 7.43 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 19.0, 22.6 (2C), 23.1 (2C), 27.9, 71.2, 73.5, 108.5, 112.4, 115.5, 118.8, 132.8, 137.8, 149.8, 155.5, 170.3; MS (70 eV): *m/z* 331 (M<sup>+</sup>, 12), 316 (19), 289 (24), 274 (100), 215 (42), 142 (94). *Anal.* Calcd. for C<sub>17</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub>S: C, 61.61; H, 6.39; N, 12.68; S, 9.67. Found: C, 61.78; H, 6.35; N, 12.94; S, 9.61.

**10-Amino-1,1,3,3-tetramethyl-2,3-dihydro-1H-pyrrolo-[3,4-b]benzo[1,5]-thiazepin-2-yloxy radical (14).** A solution of compound **13** (662 mg, 2.0 mmol) in EtOH saturated with HCl gas was heated at reflux temperature for 10 h. After cooling, the solvent was evaporated off, the residue was dissolved in saturated aq NaHCO<sub>3</sub> solution (50 mL) (caution, intense foaming!), and this solution was extracted with CHCl<sub>3</sub> (2 × 15 mL). The combined organic phases were dried (MgSO<sub>4</sub>), activated MnO<sub>2</sub> (43 mg, 0.5 mmol) was added, and O<sub>2</sub> was bubbled through for 15 min. After filtering the mixture, the solvent was evaporated off, and the residue was subjected to flash column chromatography (CHCl<sub>3</sub>/Et<sub>2</sub>O) to give the product as a pale yellow solid, 190 mg (30%), mp 155–157°C; R<sub>f</sub>: 0.33 (CHCl<sub>3</sub>/MeOH, 9:1); IR: 3319, 2970, 2924, 2853, 2223, 1653 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub> + C<sub>6</sub>F<sub>5</sub>N<sub>2</sub>H<sub>3</sub>): δ 1.21 (s, 3H), 1.25 (s, 6H), 1.34 (s, 3H), 6.24 (s, 2H), 7.04–7.28 (m, 4H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub> + C<sub>6</sub>F<sub>5</sub>N<sub>2</sub>H<sub>3</sub>): δ 23.3, 23.7, 27.0, 27.8, 69.0, 70.9, 124.4, 125.2, 128.2, 128.9, 131.8, 137.4, 147.0, 149.0, 158.0; MS (70 eV): *m/z* 288 (M<sup>+</sup>, 10), 258 (100), 226 (62), 215 (62). *Anal.* Calcd. for C<sub>15</sub>H<sub>18</sub>N<sub>3</sub>OS: C, 62.47; H, 6.29; N, 14.57; S, 11.12. Found: C, 62.42; H, 6.35; N, 14.71; S, 11.06.

**11-Hydroxy-1,1,3,3-tetramethyl-1,2,3,11-tetrahydrobenzimidazo [Q4] [2,1-b]pyrrolo[3,4-e][1,3]-thiazin-2-yloxy radical (15).** To a stirred suspension of 2-mercaptobenzimidazole (300 mg, 2.0 mmol) and DBU (638 mg, 4.2 mmol) in acetonitrile (10 mL), compound **1** (494 mg, 2.0 mmol) was added and the mixture was heated at reflux temperature for 30 min, upon which the solid dissolved. After cooling, the acetonitrile was evaporated off, the residue was dissolved in CHCl<sub>3</sub> (30 mL) and washed with brine (10 mL), and the organic phase was separated, dried (MgSO<sub>4</sub>), filtered, and evaporated. The residue was purified by flash column chromatography (hexane/EtOAc, CHCl<sub>3</sub>/Et<sub>2</sub>O) to give the title compound as a yellow solid, 474 mg (75%), mp 219–221°C; R<sub>f</sub>: 0.30 (CHCl<sub>3</sub>/Et<sub>2</sub>O, 2:1); IR: 2983, 2924, 2854, 1617 cm<sup>-1</sup>;

<sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD + C<sub>6</sub>F<sub>5</sub>N<sub>2</sub>H<sub>3</sub>): δ 1.36 (s, 3H), 1.39 (s, 3H), 1.40 (s, 3H), 1.49 (s, 3H), 6.58 (s, 1H), 7.31 (m, 2H), 7.57 (m, 1H), 7.70 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 23.1, 23.4, 24.0, 24.4, 69.0, 69.7, 73.1, 110.7, 117.0, 122.2, 123.1, 133.5, 142.4, 144.7, 149.7, 152.5; MS (70 eV): *m/z* 316 (M<sup>+</sup>, 20), 286 (239), 282 (100), 269 (83), 150 (59). *Anal.* Calcd. for C<sub>16</sub>H<sub>18</sub>N<sub>3</sub>O<sub>2</sub>S: C, 60.74; H, 5.73; N, 13.28; S, 10.13. Found: C, 60.58; H, 5.91; N, 13.41; S, 10.01.

## DECLARATION OF INTEREST

The authors declare no conflict of interest.

**Acknowledgments.** The project was supported by National Research, Development and Innovation Office (OTKA104956). The present scientific contribution is dedicated to the 650th anniversary of the foundation of the University of Pécs, Hungary.

## REFERENCES AND NOTES

- [1] Altenbach, C.; López, C. J.; Hideg, K.; Hubbell, W. L. *Methods Enzymol* 2015, 564, 59.
- [2] Lambert, K. M.; Bobbitt, J. M.; Eldirany, S. A.; Kissane, L. E.; Sheridan, R. K.; Stempel, Z. D.; Sternberg, H. F.; Bailey, F. W. *Chem A Eur J* 2016, 22, 5156.
- [3] Winter, S. M.; Hill, S.; Oakley, R. T. *J Am Chem Soc* 2015, 137, 3720.
- [4] (a) Zakrzewski, J.; Huras, B. *Beilstein J Org Chem* 2015, 11, 1155. (b) Gophane, B. D.; Sigurdsson, T. S. *Beilstein J Org Chem* 2015, 11, 219. (c) Kálai, T.; Kulcsár, G.; Jekő, J.; Ósz, E.; Sümegi, B.; Hideg, K. *ARKIVOC* 2004, vii, 266.
- [5] Sennik, E.; Sennik, B.; Alev, O.; Kilinc, N.; Yilmaz, F.; Ozturk, Z. Z. *J Appl Polym Sci* 2016, 33, 43641.
- [6] (a) Rosantzev, E. G.; Neiman, M. B. *Tetrahedron* 1964, 20, 131. (b) Rozantsev, E. G. *Free Nitroxyl Radicals*; Plenum Press: New York, 1970.
- [7] Kálai, T.; Balog, M.; Jekő, J.; Hideg, K. *Synthesis* 1998 1476.
- [8] Kálai, T.; Bagi, N.; Jekő, J.; Berente, Z.; Hideg, K. *Synthesis* 2010 1702.
- [9] Kálai, T.; Jekő, J.; Hideg, K. *Synthesis* 2000 831.
- [10] Bognár, B.; Kálai, T.; Gulyás-Fekete, G.; Lazsányi, N.; Hideg, K. *Synthesis* 2015 985.
- [11] Kálai, T.; Jekő, J.; Berente, Z.; Hideg, K. *Synthesis* 2006 439.
- [12] Kulcsár, G.; Kálai, T.; Jekő, J.; Hideg, K. *Synthesis* 2003 1361. *Chem Abs*, 1971(75), 49044.
- [13] Kálai, T.; Bognár, B.; Zsolnai, D.; Berente, Z.; Hideg, K. *Synthesis* 2012 3655.
- [14] Hankovszky, H. O.; Hideg, K. *Acta Chim Acad Sci Hung* 1971, 68, 403.
- [15] Lévai, A.; Kiss-Szikszay, A. *ARKIVOC* 2008, i, 65.
- [16] El-Bayouki, K. A. M. *J Sulfur Chem* 2011, 32, 623.
- [17] Warawa, E. J.; Migler, B. M. US patent 4879288 *Chem. Abstr.* 1988, 108, 37876.
- [18] Schmutz, J.; Hunziker, F. US patent 3539573 *Chem Abstr* 2010, 152, 75087.
- [19] Youcheng, L.; Zhongli, G.; Tongbao, K. 1988, 33, 2032. *Chem Abstr* 1989, 111, 233624.

[20] Hideg, K.; Sár, P. C.; Hankovszky, H. O.; Tamás, T.; Jerkovich, G. *Synthesis* 1993, 390.

[21] Demina, M. M.; Novopashin, P. S.; Kon'kova, T. V.; Afonin, A. V.; Sarapulova, G. I.; Afonin, A. V.; Medvedeva, A. S. *Chemistry of Heterocyclic Compounds* 2006, 42, 1457.

[22] Naeimi, H.; Heidarneshad, A. *Synth Commun* 2016, 46, 594.

[23] (a) Torrini, I.; Giampiero, P. Z.; Paglialunga Paradisi, M. *Heterocycles* 1988, 27, 401. (b) Matsudo, K.; Sunago, M.; Okutani, N.;

Takagi, T.; Nakamoto, H.; Kobayashi, M. *Chem Pharm Bull* 1995, 43, 1643.

[24] Cziráky, Z.; Kóródi, F. *Heterocycles* 1993, 36, 2475.

[25] Zhdanov, R. I. *Bioactive Spin Labels*; Berlin: Springer, 1992.

[26] Sár, P. C.; Kálai, T.; Bárász, M. N.; Jerkovich, G.; Hideg, K. *Synthetic Commun* 1995, 25, 2929.

UNCORRECTED PROOF

60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118

# Author Query Form

---

**Journal: Journal of Heterocyclic Chemistry**

**Article: jhet\_2850**

Dear Author,

During the copyediting of your paper, the following queries arose. Please respond to these by annotating your proofs with the necessary changes/additions.

- If you intend to annotate your proof electronically, please refer to the E-annotation guidelines.
- If you intend to annotate your proof by means of hard-copy mark-up, please use the standard proofing marks. If manually writing corrections on your proof and returning it by fax, do not write too close to the edge of the paper. Please remember that illegible mark-ups may delay publication.

Whether you opt for hard-copy or electronic annotation of your proofs, we recommend that you provide additional clarification of answers to queries by entering your answers on the query sheet, in addition to the text mark-up.


Query No.	Query	Remark
Q1	AUTHOR: Please give manufacturer information for all products: company name, town, state (two-letter abbreviation, if USA), and country.	
Q2	AUTHOR: "pentafluorophenyhydrazine" has been changed to "pentafluorophenyl hydrazine." Please check.	
Q3	AUTHOR: Please confirm that 2H <sub>2</sub> O is correct.	
Q4	AUTHOR: Please confirm that this heading is correct.	
Q5	AUTHOR: Please confirm that given names (red) and surnames/family names (green) have been identified correctly.	




Required software to e-annotate PDFs: **Adobe Acrobat Professional** or **Adobe Reader** (version 7.0 or above). (Note that this document uses screenshots from **Adobe Reader X**)

The latest version of Acrobat Reader can be downloaded for free at: <http://get.adobe.com/uk/reader/>

Once you have Acrobat Reader open on your computer, click on the **Comment** tab at the right of the toolbar:



This will open up a panel down the right side of the document. The majority of tools you will use for annotating your proof will be in the **Annotations** section, pictured opposite. We've picked out some of these tools below:




**1. Replace (Ins) Tool – for replacing text.**



Strikes a line through text and opens up a text box where replacement text can be entered.

**How to use it**

- Highlight a word or sentence.
- Click on the **Replace (Ins)** icon in the Annotations section.
- Type the replacement text into the blue box that appears.




**2. Strikethrough (Del) Tool – for deleting text.**



Strikes a red line through text that is to be deleted.

**How to use it**

- Highlight a word or sentence.
- Click on the **Strikethrough (Del)** icon in the Annotations section.





**3. Add note to text Tool – for highlighting a section to be changed to bold or italic.**



Highlights text in yellow and opens up a text box where comments can be entered.

**How to use it**

- Highlight the relevant section of text.
- Click on the **Add note to text** icon in the Annotations section.
- Type instruction on what should be changed regarding the text into the yellow box that appears.




**4. Add sticky note Tool – for making notes at specific points in the text.**



Marks a point in the proof where a comment needs to be highlighted.

**How to use it**

- Click on the **Add sticky note** icon in the Annotations section.
- Click at the point in the proof where the comment should be inserted.
- Type the comment into the yellow box that appears.



USING e-ANNOTATION TOOLS FOR ELECTRONIC PROOF CORRECTION


**5. Attach File Tool – for inserting large amounts of text or replacement figures.**



Inserts an icon linking to the attached file in the appropriate place in the text.

**How to use it**

- Click on the [Attach File](#) icon in the Annotations section.
- Click on the proof to where you'd like the attached file to be linked.
- Select the file to be attached from your computer or network.
- Select the colour and type of icon that will appear in the proof. Click OK.



**6. Add stamp Tool – for approving a proof if no corrections are required.**




Inserts a selected stamp onto an appropriate place in the proof.

**How to use it**

- Click on the [Add stamp](#) icon in the Annotations section.
- Select the stamp you want to use. (The [Approved](#) stamp is usually available directly in the menu that appears).
- Click on the proof where you'd like the stamp to appear. (Where a proof is to be approved as it is, this would normally be on the first page).

of the business cycle, starting with the  
 on perfect competition, constant ret  
 production. In this environment goods  
 extra profits and the number of firms  
 he number of firms is determined by  
 determined by the model. The New-Key  
 otaki (1987), has introduced produc  
 general equilibrium models with nomin  
 ed and supply shocks. Most of this literat




**7. Drawing Markups Tools – for drawing shapes, lines and freeform annotations on proofs and commenting on these marks.**

Allows shapes, lines and freeform annotations to be drawn on proofs and for comment to be made on these marks..

**How to use it**

- Click on one of the shapes in the [Drawing Markups](#) section.
- Click on the proof at the relevant point and draw the selected shape with the cursor.
- To add a comment to the drawn shape, move the cursor over the shape until an arrowhead appears.
- Double click on the shape and type any text in the red box that appears.



For further information on how to annotate proofs, click on the [Help](#) menu to reveal a list of further options:

